Main competitors
| Add to a list |
Analyst Opinion
|
4m Target Price Revision
|
4m Revision of opinion
|
Divergence of analysts' opinions
|
Divergence of Target Price
|
Average Target P.
|
Ecart obj. / dr
|
Nbr of analysts
|
---|
| | | | | | |
1,079.53
| +7.94% | 32 |
| | | | | | |
2,053.68
| +15.97% | 37 |
| | | | | | |
9,277.27
| +15.23% | 11 |
| | | | | | |
48.36
| +14.87% | 15 |
| | | | | | |
1,640.97
| +13.35% | 36 |
| | | | | | |
1,741.46
| +14.88% | 13 |
| | | | | | |
2,059.23
| +25.95% | 13 |
| | | | | | |
12,148.22
| +14.07% | 9 |
| | | | | | |
40.09
| +31.18% | 3 |
| | | | | | |
145.62
| +2.55% | 6 |
| | | | |
-
| |
181.15
| -10.14% | 2 |
| | | | | | |
3,018.50
| +7.20% | 10 |
| | | | | | |
218.75
| +33.18% | 4 |
| | | | | | |
174.38
| +8.58% | 4 |
| | | | | | |
392,602.94
| +50.71% | 16 |
| | | | | | |
8.461
| +36.57% | 5 |
|
Average
| | | | | |
26,652.41
|
+17.63%
|
14
|
|
Weighted average by Cap.
| | | | | |
8,392.81
|
+15.32%
|
22
|
Generic Pharmaceuticals